Articles

Safety analysis data of concomitant telotristat ethyl (TE) plus peptide receptor radionuclide therapy (PRRT) in patients with metastatic/nonresectable neuroendocrine tumors (NETs) and carcinoid syndrome diarrhea (CSD) indicate that the safety profile of combination treatment was consistent with individual TE and PRRT therapies. Read More ›

Real-world clinical practice data indicate that telotristat ethyl (TE) use in patients with progressive neuroendocrine tumors (NETs) may provide clinical benefit in terms of improvements in carcinoid syndrome (CS) symptoms, functional status, and weight. Read More ›

Post-hoc analytical data of the randomized phase 3 SANET-ep trial indicate that multitargeted tyrosine kinase inhibitor surufatinib therapy was associated with maintenance of health-related quality of life (HRQoL) in previously treated patients with progressive, well-differentiated, advanced extrapancreatic neuroendocrine tumors (NETs). Read More ›

Results of a dose-escalation/expansion study in the US population among patients with extrapancreatic and pancreatic neuroendocrine tumors (NETs) indicate promising antitumor activity of the multitargeted tyrosine kinase inhibitor surufatinib, with a safety profile consistent with that previously described in the SANET-ep trial. Read More ›

Subgroup analysis data of the randomized phase 3 SANET-ep trial indicate that the clinical benefits of the multitargeted tyrosine kinase inhibitor surufatinib therapy also extended to major subgroups by Ki67 and primary tumor origin in patients with advanced, well-differentiated extrapancreatic neuroendocrine tumors (NETs). Read More ›

Findings of a retrospective analysis of real-world data indicate that retreatment with 2 extra cycles of peptide receptor radionuclide therapy (PRRT) with Lu-DOTATATE provided survival benefit in patients with disease progression after initial PRRT. Read More ›

Findings of a retrospective analysis in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) indicate that peptide receptor radionuclide therapy (PRRT) with Lu-DOTATATE may provide clinical benefit and does not significantly impair health-related quality of life (HRQoL). Read More ›

Real-world safety data from the US expanded access program of Lu-DOTATATE showed that the safety profile was consistent with that previously described in clinical trials of patients with advanced midgut neuroendocrine tumors (NETs). Read More ›

The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Sibley Memorial Hospital, Washington, DC, provides a wide range of healthcare services to the area’s communities. Through integrated care with other Johns Hopkins locations, the center’s healthcare team has access to novel treatments and resources to assist in developing and delivering individualized cancer care to patients. Read More ›